To the Editor.
—In the July 1988 issue of the Archives, Lynch et al1 reported on 18 patients with central nervous system (CNS) effects during timolol maleate therapy whose condition improved after switching to betaxolol hydrochloride therapy. Unfortunately, however, they did not report on the intraocular pressure.Since betaxolol became available in the Netherlands in September 1986, we have prescribed this new antiglaucoma drug to 40 consecutive patients in whom timolol therapy was discontinued because of adverse effects. The group consisted of 27 women and 13 men, with an age range of 44 to 85 years (mean ± SD, 69.5 ± 9.2 years). Follow-up ranged from three to 21 months (10.75 ± 5.0 months). We excluded all patients in whom the alleged side effects did not disappear after stopping both timolol and betaxolol therapies and made no changes in the concomitant ocular or systemic medication. Although several patients were
de Vries J, van de Merwe SA, de Heer LJ. From Timolol to Betaxolol. Arch Ophthalmol. 1989;107(5):634. doi:10.1001/archopht.1989.01070010652006